KRAS and cancer: The study aims to provide Ulixertinib (BVD-523) for compassionate use in patients with advanced cancer whose solid tumors have been affected by the MAPK pathway, such as KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations, which do not fully respond to current treatment or have exhausted their available therapeutic options.